Stay updated on Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page
- Check6 days agoChange DetectedThe page’s references section now shows an updated CABOSUN trial citation line including the associated erratum entries. The site footer revision/version tag was also updated from v3.5.0 to v3.5.3.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check41 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No changes to study content are evident in the screenshot.SummaryDifference0.0%

- Check56 days agoChange DetectedFooter revision updated to v3.4.3; the previous v3.4.2 label was removed.SummaryDifference0.0%

- Check78 days agoChange DetectedFooter now displays Revision: v3.4.2, replacing the previous Revision: v3.4.1.SummaryDifference0.0%

- Check85 days agoChange DetectedRevision reflects an update from v3.4.0 to v3.4.1 with no visible changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check99 days agoChange DetectedAdded Show glossary / Hide glossary options and updated metadata labels to reflect Revision: v3.4.0 (Last Update Submitted that Met QC Criteria; No FEAR Act Data).SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.